Physician profile
Rafael Rodriguez
NPI 1144298175
$19,374.31
in general payments reported to CMS, 2019-2025
52 companies · $2,855 in 2025
The $2,855 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,879 · 2020: $2,520 · 2021: $3,340 · 2022: $3,082 · 2023: $2,082 · 2024: $2,616 · 2025: $2,855.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,390 · Education: $163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,389.56 |
| Education | $163.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,980.28 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $1,515.59 | 2019-2025 | Qulipta, Vraylar, Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,154.90 | 2019-2025 | Jardiance, Synjardy |
| Novo Nordisk INC | $1,095.72 | 2019-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $1,017.02 | 2021-2025 | |
| Medtronic, INC. | $940.01 | 2021-2025 | Hawkone |
| Lilly USA, LLC | $905.01 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Gilead Sciences, INC. | $838.19 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $830.24 | 2019-2024 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $641.11 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Allergan, INC. | $614.51 | 2019-2020 | |
| Ardelyx, INC. | $512.56 | 2023-2025 | Ibsrela |
| Amgen INC. | $499.05 | 2020-2025 | Repatha, Otezla, Repatha |
| Sanofi-Aventis U.S. LLC | $436.62 | 2019-2023 | |
| Amarin Pharma, INC. | $424.48 | 2019-2022 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rafael Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.